#United States #South San Francisco #Rigel Pharmaceuticals #VEPPANU™ #vepdegestrant

Rigel Pharmaceuticals Enters Licensing Agreement for VEPPANU™

On May 12, 2026, Rigel Pharmaceuticals, Inc. made headlines by announcing an exclusive global licensing agreement with Arvinas, Inc. and Pfizer Inc. to develop and market VEPPANU™ (vepdegestrant), marking a significant advancement in the treatment of advanced breast cancer. VEPPANU™ is particularly designed for patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer (mBC).

A New Era in Breast Cancer Treatment

The introduction of VEPPANU™ heralds what could be a groundbreaking shift in breast cancer treatment modalities. This oral PROTAC (PROteolysis TArgeting Chimera) therapy operates via a novel mechanism that selectively degrades harmful proteins rather than inhibiting them, a pivotal shift that may offer new hope to patients experiencing resistance to conventional hormone therapies.

The efficacy of VEPPANU™ has been demonstrated in pivotal Phase 3 clinical trials, particularly the VERITAC-2 trial. Results show that vepdegestrant significantly improves progression-free survival (PFS) versus fulvestrant, with patients experiencing PFS of 5.0 months compared to 2.1 months with the older treatment. This dramatic enhancement highlights VEPPANU™'s potential as a vital option for patients facing limited alternatives after endocrine therapy.

Transaction Overview and Strategic Implications

Under this agreement, Rigel is positioned to acquire the rights to develop and commercialize VEPPANU™, providing a substantial boost to its portfolio aimed at treating hematologic disorders and cancer. Rigel will pay Arvinas and Pfizer $70 million upfront, with an additional $15 million contingent upon meeting certain developmental milestones. The agreement also outlines up to $320 million in future milestone payments based on regulatory and commercial successes.

Raul Rodriguez, Rigel's president and CEO, emphasized the strategic importance of VEPPANU™ in addressing the needs of patients who have few options post-endocrine therapy. He noted that the medication's unique mechanism of action could effectively counter treatment resistance, a significant obstacle faced by half of ER+/HER2- mBC patients who develop ESR1 mutations after standard therapies.

Clinical Significance and Future Outlook

The approval process for VEPPANU™ has already made considerable progress. As of May 1, 2026, the FDA approved the drug for adult patients whose cancer has advanced despite previous endocrine therapy. Clinical trial data published in the prestigious New England Journal of Medicine reinforces the therapeutic value of VEPPANU™, substantiating not just its efficacy in improving patient survival rates but also its robust safety profile with primarily low-grade side effects.

As excitement builds around VEPPANU™, professional organizations like the National Comprehensive Cancer Network (NCCN) have also endorsed its use as a Category 2A treatment option. This seal of approval underscores the drug's standing as a crucial addition to oncology treatment guidelines.

The Future of Rigel Pharmaceuticals

With VEPPANU™, Rigel anticipates a significant avenue for revenue growth and expansion in its commercial strategy. The company will leverage its extensive network, advanced technical capabilities, and experienced sales team to successfully launch and promote this innovative therapy.

As noted by Erika Hamilton, M.D., the principal investigator of the VERITAC-2 trial, VEPPANU™ is poised to fill a critical gap in treatment options for breast cancer patients, ushering in a new era of targeted therapies designed to overcome the limitations of existing treatments.

Rigel's focus on launching VEPPANU™ not only signifies an important milestone for the company but also an essential step forward in providing hope and effective treatment options for patients grappling with advanced breast cancer.

In conclusion, the licensing of VEPPANU™ presents Rigel Pharmaceuticals with a transformative opportunity, and as the healthcare community gears up for its launch, all eyes will be on how this new therapy impacts patient outcomes in the challenging landscape of breast cancer treatment.